The stellar success of blockbuster drugs like Ozempic, Wegovy, Mounjaro and Zepbound has companies eager to break into the lucrative weight loss drug market — here are the hopeful rivals preparing to challenge Eli Lilly and Novo Nordisk for dominance in the obesity drug gold rush.
There is no guarantee promising results on efficacy, safety and tolerability from earlier trials will be replicated in larger late-stage trials. Even companies with candidates already in the later stages of testing are still going to require several years to gather and process the data and, should things pan out, time to work with regulators to secure approval.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen: